KOREA
Contract Service
E11
Contract Service
Analytical Equipment, Cell & Gene therapy, Stability Testing of Drugs
NeXST is Nexel's pharmacology test service for cardiac safety that predicts and evaluates the risk and harmfulness of the human heart using hiPSC-CM to enable more efficient development of new drugs.
Nexel Co., Ltd. is the only company in Korea that is participating in the revision of ICH guidelines as a member of HESI CiPA Working Group. Our cardiac safety pharmacology test platform has verified the exact derivation of results using various standard reagents, and offers services using Cardiosight®-S, a self-produced iPSC-derived cardiomyocyte, to suggest flexible experimental design and reasonable costs.